C. Michael Gibson MD· @CMichaelGibson · X·· 11 小时前评分70
正文 · 原文
In patients with HER2-positive advanced #breastcancer, the HER2-targeted bispecific antibody #anbenitamab plus albumin-bound docetaxel led to 24-month progression-free survival of 58.5%, as compared with 34.4% with standard therapy.
#ESMO26
https://nej.md/4BcWlF3
212 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org来源：C. Michael Gibson MD · x.com